1,721,228 research outputs found
Impiego clinico degli inibitori GP IIb/IIIa eptifibatide e tirofiban nel trattamento delle sindromi coronariche acute di tipo "non sopraslivellamento del tratto ST".
No full text
Real-world cost effectiveness of MitraClip combined with Medical Therapy Versus Medical therapy alone in patients with moderate or severe mitral regurgitation
No full textDifferent implications of the early drop in cholesterol, level in patients admitted for myocardial infarction or unstable angina: The LATIN study
No full textBeta-blocker utilization in congestive heart failure: A survey on 4408 Italian outpatients over the last two years
No full textBackground: Several trials have shown that beta-blockers (βB) reduce morbidity and mortality of the pts with congestive heart failure (CHF). However, only a minority of pts who might benefit from this treatment are actually treated.Aims of the study were to evaluate in a large population of Italian outpatients: (a) the rate of use of βB over the last two years; (b) clinical determinants associated with their utilization.Methods: Data were collected by locally trained clinicians using an ad-hoc software. Univariate and multivariate analyses were performed to evaluate the association between clinical variables and βB prescription.Results: A total of 4408 pts entered the database. Overall, 498 (11.3%) pts were on treatment with βB at study entry. The rate of prescription increased from 9% to 15.7% (March 1995 to January 1997) (p < 0.001). The relationship between clinical-epidemiological variables and βB prescription is shown in the table. At unadjusted analysis, while EF% and the presence of ventricular tachycardia (VT) did not affect βB prescription, younger age, CHF due to DCM, NYHA class I-II vs III-IV were significantly associated with a higher rate of βB utilization.Multivariate analysis showed that younger age and DCM etiology were independently associated with more βB prescriptions (OR 2.11 95%Cl 1.65-2.71 and OR 1.35 95% Cl 1.09-1.69).Conclusions: The rate of βB prescriptions significantly increased over the last 2 year among outpatients with CHF. Among these pts, the subgroups at lower risk are more likely to be treated with βB
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009.
No full textThis European consensus document aims to identify the main reasons for the apparent lack of progress in the introduction of new medicines for acute heart failure. Relevant issues include not only the heterogeneity of the patient group but also the pharmacology of the medicines themselves and the design of the trials. Above all, this document attempts to provide some pragmatic solutions to this complex syndrome to simplify the execution of meaningful therapeutic endeavours in this area of undoubted unmet clinical need in the future
FREQUENCY OF PREDISCHARGE VENTRICULAR ARRHYTHMIAS IN POSTMYOCARDIAL INFARCTION PATIENTS DEPENDS ON RESIDUAL LEFT-VENTRICULAR PUMP PERFORMANCE AND IS INDEPENDENT OF THE OCCURRENCE OF ACUTE REPERFUSION
No full textClinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009
No full textThis European consensus document aims to identify the main reasons for the apparent lack of progress in the introduction of new medicines for acute heart failure. Relevant issues include not only the heterogeneity of the patient group but also the pharmacology of the medicines themselves and the design of the trials. Above all, this document attempts to provide some pragmatic solutions to this complex syndrome to simplify the execution of meaningful therapeutic endeavours in this area of undoubted unmet clinical need in the future
- …
